Impact Partnership Wealth LLC Makes New Investment in Cencora, Inc. $COR

Impact Partnership Wealth LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the first quarter, HoldingsChannel reports. The institutional investor bought 3,723 shares of the company’s stock, valued at approximately $1,170,000.

Other hedge funds have also made changes to their positions in the company. AustralianSuper Pty Ltd purchased a new stake in Cencora in the third quarter worth about $26,191,000. Chilton Investment Co. Inc. bought a new position in Cencora during the 3rd quarter worth about $459,000. Nordea Investment Management AB increased its position in Cencora by 3.8% during the 4th quarter. Nordea Investment Management AB now owns 1,256,356 shares of the company’s stock valued at $426,715,000 after purchasing an additional 45,712 shares during the period. Groupama Asset Managment purchased a new position in Cencora during the 3rd quarter valued at about $1,225,000. Finally, Assetmark Inc. raised its holdings in shares of Cencora by 57.0% in the 4th quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock valued at $22,724,000 after purchasing an additional 24,431 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Up 0.6%

NYSE:COR opened at $283.24 on Wednesday. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The stock has a market capitalization of $55.11 billion, a P/E ratio of 21.72, a P/E/G ratio of 1.56 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The company’s 50-day simple moving average is $279.15 and its 200-day simple moving average is $321.28.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its Board of Directors has initiated a stock buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio is presently 18.40%.

Insider Activity

In other Cencora news, Director Lauren M. Tyler acquired 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

COR has been the subject of several research reports. Citigroup lowered their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. UBS Group boosted their price objective on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings lowered Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. William Blair started coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. Finally, Morgan Stanley set a $342.00 price target on Cencora in a report on Friday, May 8th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.